Johan M. van Rooijen

1.9k total citations
16 papers, 224 citations indexed

About

Johan M. van Rooijen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Johan M. van Rooijen has authored 16 papers receiving a total of 224 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Johan M. van Rooijen's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Genomics and Diagnostics (4 papers) and HER2/EGFR in Cancer Research (3 papers). Johan M. van Rooijen is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Genomics and Diagnostics (4 papers) and HER2/EGFR in Cancer Research (3 papers). Johan M. van Rooijen collaborates with scholars based in Netherlands, United States and Germany. Johan M. van Rooijen's co-authors include Elisabeth G.E. de Vries, Carolien P. Schröder, Mathijs P. Hendriks, Albert J. ten Tije, James E. Boers, Cornelis J.A. Punt, G.J. Creemers, Stefan Sleijfer, Johannes J.M. Kwakman and Martijn P. Lolkema and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Johan M. van Rooijen

16 papers receiving 221 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johan M. van Rooijen Netherlands 8 145 58 49 39 38 16 224
Trevor Feinstein United States 8 166 1.1× 73 1.3× 52 1.1× 40 1.0× 53 1.4× 27 248
Giuseppa Maltese Italy 11 115 0.8× 85 1.5× 43 0.9× 36 0.9× 84 2.2× 25 394
Laura Matteucci Italy 6 141 1.0× 38 0.7× 78 1.6× 58 1.5× 62 1.6× 15 272
Vincenzo Famiglietti Italy 9 219 1.5× 92 1.6× 60 1.2× 48 1.2× 45 1.2× 27 281
Silvana Acquafredda Italy 6 159 1.1× 94 1.6× 40 0.8× 22 0.6× 24 0.6× 8 237
Yang Lv China 12 189 1.3× 80 1.4× 76 1.6× 29 0.7× 47 1.2× 24 312
Toshitaka Sugawara Japan 9 182 1.3× 70 1.2× 50 1.0× 16 0.4× 98 2.6× 24 304
Burcin Özdirik Germany 12 112 0.8× 55 0.9× 41 0.8× 34 0.9× 69 1.8× 24 319
V. Leonardi Italy 10 188 1.3× 85 1.5× 53 1.1× 14 0.4× 33 0.9× 33 269
Catherine Leyh Germany 6 78 0.5× 57 1.0× 55 1.1× 16 0.4× 64 1.7× 17 225

Countries citing papers authored by Johan M. van Rooijen

Since Specialization
Citations

This map shows the geographic impact of Johan M. van Rooijen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan M. van Rooijen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan M. van Rooijen more than expected).

Fields of papers citing papers by Johan M. van Rooijen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan M. van Rooijen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan M. van Rooijen. The network helps show where Johan M. van Rooijen may publish in the future.

Co-authorship network of co-authors of Johan M. van Rooijen

This figure shows the co-authorship network connecting the top 25 collaborators of Johan M. van Rooijen. A scholar is included among the top collaborators of Johan M. van Rooijen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan M. van Rooijen. Johan M. van Rooijen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Joode, Karlijn de, Geert J.L.H. van Leenders, Paul Hamberg, et al.. (2023). The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies. Scientific Reports. 13(1). 10720–10720. 3 indexed citations
2.
Verhoeven, Rob H.A., Wouter B. Nagengast, Vera Oppedijk, et al.. (2022). Managed Clinical Network for esophageal cancer enables reduction of variation between hospitals trends in treatment strategies, lead time, and 2-year survival. European Journal of Surgical Oncology. 49(1). 106–112. 3 indexed citations
3.
Smid, Marcel, Job van Riet, Lindsay Angus, et al.. (2021). Author Correction: Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nature Communications. 12(1). 3269–3269. 6 indexed citations
4.
Smid, Marcel, Job van Riet, Lindsay Angus, et al.. (2021). Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Nature Communications. 12(1). 574–574. 45 indexed citations
5.
Rooijen, Johan M. van, et al.. (2021). Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice. European Urology Open Science. 33. 48–55. 3 indexed citations
6.
Zanden, Jelmer J. van, et al.. (2019). Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers. Anti-Cancer Drugs. 30(4). 410–415. 10 indexed citations
7.
Rooijen, Johan M. van, Si-Qi Qiu, Hetty Timmer‐Bosscha, et al.. (2018). Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2–positive breast cancer. European Journal of Cancer. 103. 52–60. 20 indexed citations
8.
Kwakman, Johannes J.M., Lieke H. J. Simkens, Johan M. van Rooijen, et al.. (2017). Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Annals of Oncology. 28(6). 1288–1293. 47 indexed citations
9.
Kwakman, Johannes J.M., Geraldine R. Vink, Laurens V. Beerepoot, et al.. (2017). Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. International Journal of Clinical Oncology. 23(3). 482–489. 27 indexed citations
10.
Kwakman, Johannes J.M., Lieke H. J. Simkens, Johan M. van Rooijen, et al.. (2017). Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group. European Journal of Cancer. 72. S5–S5. 1 indexed citations
11.
Rooijen, Johan M. van, Linda de Munck, Jacques C. de Graaf, et al.. (2015). Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice. Anti-Cancer Drugs. 27(2). 127–132. 6 indexed citations
12.
Rooijen, Johan M. van, et al.. (2015). Immunotherapeutic options on the horizon in breast cancer treatment. Pharmacology & Therapeutics. 156. 90–101. 18 indexed citations
13.
Bensch, Frederike, Johan M. van Rooijen, Carolien P. Schröder, & Anna K.L. Reyners. (2014). A 21-Year-Old Patient With a HER2-Positive Colorectal Cancer. Gastroenterology. 148(1). 20–21. 4 indexed citations
14.
Rooijen, Johan M. van, et al.. (2014). Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study. European Journal of Cancer. 50(5). 885–891. 6 indexed citations
15.
Rooijen, Johan M. van, et al.. (2011). Hydrocephalus, a Rare Manifestation of Sarcoidosis. SHILAP Revista de lepidopterología. 1(3). e66–e66. 11 indexed citations
16.
Rooijen, Johan M. van, et al.. (2008). Left atrial impression: a sign of extra-cardiac pathology. European Journal of Echocardiography. 9(5). 661–664. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Trevor Feinstein Breakdown of academic impact, for papers by Giuseppa Maltese Breakdown of academic impact, for papers by Laura Matteucci Breakdown of academic impact, for papers by Vincenzo Famiglietti Breakdown of academic impact, for papers by Silvana Acquafredda Breakdown of academic impact, for papers by Yang Lv Breakdown of academic impact, for papers by Toshitaka Sugawara Breakdown of academic impact, for papers by Burcin Özdirik Breakdown of academic impact, for papers by V. Leonardi Breakdown of academic impact, for papers by Catherine Leyh
Rankless by CCL
2026